University of Hawaii, internal Medicine Residency Program, Honolulu, HI, USA.
Faculty of Medicine Vajira Hospital, Navamindradhiraj University, Bangkok, Thailand.
Jpn J Clin Oncol. 2019 Oct 1;49(10):924-931. doi: 10.1093/jjco/hyz099.
Both haplo-identical transplant (haplo) and umbilical cord transplant (UC) are valuable graft options for patients without available matched relative. Previous studies showed inconsistent outcomes comparing Post transplant Cyclophosphamide based haplo (PTCy-haplo) and UC; therefore, we attempt to compare the studies by mean of meta-analysis.
We searched for titles of articles in MEDLINE (PubMed), Cochrane library, EMBASE database and Google scholar that compared transplantation with PTCy-haplo versus UC. We conducted a random-effect meta-analysis of seven studies involving a total of 3434 participants and reported the pooled odd ratios (OR) of acute graft-versus-host disease (aGVHD), chronic graft-versus-host disease (cGVHD), relapse and overall survival (OS) between PTCy-haplo and UC groups.
We found a significantly decreased risk of aGVHD and relapse in the PTCy-haplo group compared to the UC group with a pooled OR of 0.78, 95% Confidence Interval (CI) 0.67-0.92, I2=0%, and 0.74, 95% CI 0.57-0.97, I2=23.9% respectively. We also found a significantly increased rate of cGVHD and OS with a pooled OR of 1.41, 95% CI 1.02-1.95, I2=56.8%, and 1.77, 95% CI 1.1-2.87, I2=82.5%, respectively.
Our meta-analysis of clinical trials demonstrated superior outcome from PTCy-haplo group compared to the UC group in terms of decreased rate of aGVHD and relapse as well as the increased rate of OS but inferior in terms of increased cGVHD risk compared to UC transplant.
对于没有合适亲属供体的患者,半相合移植(haplo)和脐带血移植(UC)都是有价值的移植物选择。先前的研究表明,基于环磷酰胺的haplo(PTCy-haplo)与 UC 之间的移植结果不一致;因此,我们尝试通过荟萃分析来比较这些研究。
我们在 MEDLINE(PubMed)、Cochrane 图书馆、EMBASE 数据库和 Google 学术中搜索了比较 PTCy-haplo 与 UC 移植的文章标题。我们对涉及 3434 名参与者的七项研究进行了随机效应荟萃分析,并报告了 PTCy-haplo 组与 UC 组之间急性移植物抗宿主病(aGVHD)、慢性移植物抗宿主病(cGVHD)、复发和总生存率(OS)的合并优势比(OR)。
与 UC 组相比,PTCy-haplo 组发生 aGVHD 和复发的风险显著降低,合并 OR 分别为 0.78(95%CI 0.67-0.92,I2=0%)和 0.74(95%CI 0.57-0.97,I2=23.9%)。我们还发现,cGVHD 和 OS 的发生率也显著增加,合并 OR 分别为 1.41(95%CI 1.02-1.95,I2=56.8%)和 1.77(95%CI 1.1-2.87,I2=82.5%)。
我们对临床试验的荟萃分析表明,与 UC 组相比,PTCy-haplo 组在降低 aGVHD 和复发率以及提高 OS 率方面具有更好的结果,但在增加 cGVHD 风险方面逊于 UC 移植。